Home » Stocks » NSTG

NanoString Technologies, Inc. (NSTG)

Stock Price: $52.30 USD 2.66 (5.36%)
Updated December 1, 9:43 AM EST - Market open

Stock Price Chart

Key Info

Market Cap 2.30B
Revenue (ttm) 117.99M
Net Income (ttm) -63.09M
Shares Out 44.07M
EPS (ttm) -1.70
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day December 1
Last Price $52.30
Previous Close $49.64
Change ($) 2.66
Change (%) 5.36%
Day's Open 48.51
Day's Range 50.38 - 52.30
Day's Volume 364,619
52-Week Range 16.01 - 52.30

More Stats

Market Cap 2.30B
Enterprise Value 2.27B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 44.07M
Float n/a
EPS (basic) -1.60
EPS (diluted) -1.70
FCF / Share -2.71
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3.83M
Short Ratio 5.72
Short % of Float n/a
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 19.53
PB Ratio 20.69
Revenue 117.99M
Operating Income -91.70M
Net Income -63.09M
Free Cash Flow -103.18M
Net Cash 29.67M
Net Cash / Share 0.67
Gross Margin 69.10%
Operating Margin -77.72%
Profit Margin -53.50%
FCF Margin -87.45%
ROA -20.71%
ROE -72.02%
ROIC -14.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (6)

Buy 3
Overweight 1
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$45.67*
(-12.68% downside)
Low
43.0
Current: $52.30
High
52.0
Target: 45.67
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12610711586.4962.6747.5931.4022.9717.8011.73
Revenue Growth17.65%-7.11%32.86%38.01%31.67%51.56%36.7%29.06%51.75%-
Gross Profit81.5370.4083.0356.2436.5426.4416.3910.618.022.60
Operating Income-82.70-69.39-38.20-41.18-41.24-46.02-28.50-16.51-10.50-12.97
Net Income-40.70-77.40-43.56-47.09-45.58-50.04-29.28-17.71-10.93-12.77
Shares Outstanding34.5927.8823.7320.1219.0317.847.640.360.320.32
Earnings Per Share-1.18-2.78-1.84-2.34-2.40-2.80-4.44-71.10-50.10-54.17
Operating Cash Flow-89.42-54.07-51.66-6.08-43.36-38.06-31.35-14.81-10.69-10.97
Capital Expenditures-7.89-4.49-4.28-3.99-3.79-1.90-0.76-0.43-2.69-1.93
Free Cash Flow-97.31-58.55-55.94-10.07-47.15-39.96-32.11-15.24-13.38-12.90
Cash & Equivalents15794.0077.7074.1849.1972.3742.8621.8711.05-
Total Debt11358.4048.9347.4241.2330.2518.2912.761.89-
Net Cash / Debt43.7735.6028.7726.767.9642.1224.569.119.16-
Assets26014813712692.8710264.3737.4124.58-
Liabilities15611196.6511472.6557.2632.9027.5413.08-
Book Value10436.8740.1112.3120.2244.8131.47-93.76-69.45-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name NanoString Technologies, Inc.
Country United States
Employees 551
CEO Robert Bradley Gray

Stock Information

Ticker Symbol NSTG
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: NSTG
IPO Date June 26, 2013

Description

NanoString Technologies provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and pan cancer and 360 gene expression, CAR-T characterization, neuropathology and neuro-inflammation gene expression, autoimmune disease gene expression, miRNA expression, human organ transplant, human and mouse metabolic pathway, and human and mouse fibrosis panels. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq molecular profiling system to determine and analyze gene sequences within biological samples. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; Astellas Pharma, Inc.; and Oregon Health & Science University for the development of novel GeoMx® Digital Spatial Profiler protein assays to spatially profile breast cancer. NanoString Technologies, Inc. was founded in 2003 and is headquartered in Seattle, Washington.